Mechanism of action of clinically approved adjuvants

Current Opinion in Immunology

Volumn 21, Issue 1, 2009, Pages 23-29

  Lambrecht, Bart N ^a,b   Kool, Mirjam ^b   Willart, Monique AM ^a   Hammad, Hamida ^a  

^a GHENT UNIVERSITY   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM; ALUMINUM HYDROXIDE; ALUMINUM HYDROXYCARBONATE; ALUMINUM HYDROXYPHOSPHATE; ALUMINUM OXYHYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM POTASSIUM SULFATE; AS 02; AS3; CHEMOKINE; CRYOPYRIN; HYDROXIDE; IMMUNOSTIMULATING AGENT; INFLAMMASOME; MAGNESIUM HYDROXIDE; MULTIPROTEIN COMPLEX; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; QS 21; UNCLASSIFIED DRUG; URIC ACID; VACCINE;

DENDRITIC CELL; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INJECTION SITE; INNATE IMMUNITY; NONHUMAN; REVIEW; STROMA CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; CARRIER PROTEINS; CELL DIFFERENTIATION; CYTOKINES; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; LIQUID CRYSTALS; POLYSORBATES; SAPONINS; SQUALENE; TH2 CELLS; URIC ACID;

EID: 64049085035     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2009.01.004     Document Type: Review

References (66)

1. Janeway Jr. C.A. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54 Pt 1 (1989) 1-13
2. Brewer J.M., and Alexander J. Cytokines and the mechanisms of action of vaccine adjuvants. Cytokines Cell Mol Ther 3 (1997) 233-246
3. DeSmedt T., Pajak B., Muraille E., Lespagnard L., Heinen E., DeBaetselier P., Urbain J., Leo O., and Moser M. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 184 (1996) 1413-1424
4. De Becker G., Moulin V., Pajak B., Bruck C., Francotte M., Thiriart C., Urbain J., and Moser M. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol 12 (2000) 807-815
5. Shah J.A., Darrah P.A., Ambrozak D.R., Turon T.N., Mendez S., Kirman J., Wu C.Y., Glaichenhaus N., and Seder R.A. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. J Exp Med 198 (2003) 281-291
6. Fujii S., Shimizu K., Smith C., Bonifaz L., and Steinman R.M. Activation of natural killer T cells by alfa galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein antigen. J Exp Med 198 (2003) 267-279
7. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
8. Sornasse T., Flamand V., De Becker G., Bazin H., Tielemans F., Thielemans K., Urbain J., Leo O., and Moser M. Antigen pulsed dendritic cells can efficiently induce an antibody response in vivo. J Exp Med 175 (1992) 15-21
9. Shi Y., Evans J.E., and Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425 (2003) 516-521
10. Idzko M., Hammad H., van Nimwegen M., Kool M., Willart M.A., Muskens F., Hoogsteden H.C., Luttmann W., Ferrari D., Di Virgilio F., et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med 13 (2007) 913-919. For the first time, it is shown that extracellular ATP acts as an adjuvant to induce Th2 sensitization in the lungs. Targeting the purinergic receptors during secondary challenge suppresses inflammation. Finding the precise purinergic receptors involved is a challenge for the future.
11. Bendelac A., and Medzhitov R. Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J Exp Med 195 (2002) F19-23
12. Naim J.O., van Oss C.J., Wu W., Giese R.F., and Nickerson P.A. Mechanisms of adjuvancy: I - metal oxides as adjuvants. Vaccine 15 (1997) 1183-1193
13. Hem S.L., Johnston C.T., and HogenEsch H. Imject Alum is not aluminum hydroxide adjuvant or aluminum phosphate adjuvant. Vaccine 25 (2007) 4985-4986
14. Brewer J.M., Conacher M., Hunter C.A., Mohrs M., Brombacher F., and Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 163 (1999) 6448-6454
15. Brewer J.M., Conacher M., Gaffney M., Douglas M., Bluethmann H., and Alexander J. Neither interleukin-6 nor signalling via tumour necrosis factor receptor-1 contribute to the adjuvant activity of Alum and Freund's adjuvant. Immunology 93 (1998) 41-48
16. Brewer J.M., Conacher M., Satoskar A., Bluethmann H., and Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 26 (1996) 2062-2066
17. Jordan M.B., Mills D.M., Kappler J., Marrack P., and Cambier J.C. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304 (2004) 1808-1810
18. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., and Nemazee D. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signalling. Science 314 (2006) 1936-1938
19. Brewer J.M. (How) do aluminium adjuvants work?. Immunol Lett 102 (2006) 10-15
20. Mannhalter J.W., Neychev H.O., Zlabinger G.J., Ahmad R., and Eibl M.M. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin Exp Immunol 61 (1985) 143-151
21. Goto N., and Akama K. Histopathological studies of reactions in mice injected with aluminum-adsorbed tetanus toxoid. Microbiol Immunol 26 (1982) 1121-1132
22. Goto N., Kato H., Maeyama J., Shibano M., Saito T., Yamaguchi J., and Yoshihara S. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 15 (1997) 1364-1371
23. 2+ signaling by alum in B cells.
24. Wijburg O.L., van den Dobbelsteen G.P., Vadolas J., Sanders A., Strugnell R.A., and van Rooijen N. The role of macrophages in the induction and regulation of immunity elicited by exogenous antigens. Eur J Immunol 28 (1998) 479-487
25. Bomford R. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. Clin Exp Immunol 39 (1980) 435-441
26. Grun J.L., and Maurer P.H. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol 121 (1989) 134-145
27. Serre K., Mohr E., Toellner K.M., Cunningham A.F., Granjeaud S., Bird R., and MacLennan I.C. Molecular differences between the divergent responses of ovalbumin-specific CD4 T cells to alum-precipitated ovalbumin compared to ovalbumin expressed by Salmonella. Mol Immunol 45 (2008) 3558-3566. Very stimulating paper that uses array technology to look at early T cell differentiation in response to ovalbumin in alum.
28. Sun H., Pollock K.G., and Brewer J.M. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 21 (2003) 849-855
29. Li H., Nookala S., and Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 178 (2007) 5271-5276. First paper on IL-1beta production and caspase-1 in mediating the effects of alum. This paper fired up the search for the involvement of NALP3.
30. Lindblad E.B. Are mineral adjuvants triggering TLR2/TLR4 on dendritic cells by a secondary cascade reaction in vivo through the action of heat shock proteins and danger signals?. Vaccine 24 (2006) 697-698
31. Kool M., Soullie T., van Nimwegen M., Willart M.A., Muskens F., Jung S., Hoogsteden H.C., Hammad H., and Lambrecht B.N. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205 (2008) 869-882. Here, uricase treatment of mice is shown to abolish the adjuvant effects of alum. By using conditional DC-deficient mice and reconstituting with monocytes, the authors demonstrate that alum adjuvant works via stimulation of monocytic precursors to DCs.
32. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., O'Hagan D., Rappuoli R., and De Gregorio E. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 105 (2008) 10501-10506. This paper illustrates how potent the local response to alum injection can be on the recruitment of innate immune cells.
33. Ulanova M., Tarkowski A., Hahn-Zoric M., and Hanson L.A. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 69 (2001) 1151-1159
34. Seubert A., Monaci E., Pizza M., O'Hagan D., and Wack A. The adjuvants aluminium hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation to dendritic cells. J Immunol 180 (2008) 5402-5412. This study supports the concept that alum mainly acts on the precursor monocyte for DCs.
35. Schnare M., Barton G.M., Holt A.C., Takeda K., Akira S., and Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2 (2001) 947-950
36. Martinon F., and Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 14 (2007) 10-22
37. Ting J.P., Willingham S.B., and Bergstralh D.T. NLRs at the intersection of cell death and immunity. Nat Rev Immunol 8 (2008) 372-379
38. Agostini L., Martinon F., Burns K., McDermott M.F., Hawkins P.N., and Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20 (2004) 319-325
39. Fritz J.H., Ferrero R.L., Philpott D.J., and Girardin S.E. Nod-like proteins in immunity, inflammation and disease. Nat Immunol 7 (2006) 1250-1257
40. Mayor A., Martinon F., De Smedt T., Petrilli V., and Tschopp J. A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses. Nat Immunol 8 (2007) 497-503
41. ••].
42. ••].
43. ••].
44. ••] has shown almost simultaneously an important role for the NALP3 inflammasome in explaining the effects of alum.
45. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., Fitzgerald K.A., and Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9 (2008) 847-856. This is an excellent explanation of the way phagocytosed crystals can activate caspase-1 via a pathway involving cathepsin B and NALP3 activation.
46. Halle A., Hornung V., Petzold G.C., Stewart C.R., Monks B.G., Reinheckel T., Fitzgerald K.A., Latz E., Moore K.J., and Golenbock D.T. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9 (2008) 857-865
47. De Gregorio E., Tritto E., and Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 38 (2008) 2068-2071
48. Pasare C., and Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 438 (2005) 364-368
49. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., and Nemazee D. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314 (2006) 1936-1938
50. Davis C.N., Mann E., Behrens M.M., Gaidarova S., Rebek M., Rebek Jr. J., and Bartfai T. MyD88-dependent and -independent signaling by IL-1 in neurons probed by bifunctional Toll/IL-1 receptor domain/BB-loop mimetics. Proc Natl Acad Sci U S A 103 (2006) 2953-2958
51. Dostert C., Petrilli V., Van Bruggen R., Steele C., Mossman B.T., and Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320 (2008) 674-677
52. Martinon F., Petrilli V., Mayor A., Tardivel A., and Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 (2006) 237-241
53. Goto N., Kato H., Maeyama J., Eto K., and Yoshihara S. Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine 11 (1993) 914-918
54. Becker B.F. Towards the physiological function of uric acid. Free Radic Biol Med 14 (1993) 615-631
55. Hassoun P.M., Yu F.S., Cote C.G., Zulueta J.J., Sawhney R., Skinner K.A., Skinner H.B., Parks D.A., and Lanzillo J.J. Upregulation of xanthine oxidase by lipopolysaccharide, interleukin-1, and hypoxia. Role in acute lung injury. Am J Respir Crit Care Med 158 (1998) 299-305
56. Liu-Bryan R., Scott P., Sydlaske A., Rose D.M., and Terkeltaub R. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 52 (2005) 2936-2946
57. Scott P., Ma H., Viriyakosol S., Terkeltaub R., and Liu-Bryan R. Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. J Immunol 177 (2006) 6370-6378
58. Ng G., Sharma K., Ward S.M., Desrosiers M.D., Stephens L.A., Schoel W.M., Li T., Lowell C.A., Ling C.C., Amrein M.W., et al. Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity 29 (2008) 807-818. In this paper investigators used atomic force microscopy to study how uric acid crystals can lead to membrane changes that eventually lead to the activation of spleen tyrosine kinase.
59. Popa-Nita O., Rollet-Labelle E., Thibault N., Gilbert C., Bourgoin S.G., and Naccache P.H. Crystal-induced neutrophil activation. IX. Syk-dependent activation of class Ia phosphatidylinositol 3-kinase. J Leukoc Biol 82 (2007) 763-773. This is the first paper to illustrate a Syk-dependent pathway for uric acid recognition in neutrophils.
60. Behrens M.D., Wagner W.M., Krco C.J., Erskine C.L., Kalli K.R., Krempski J., Gad E.A., Disis M.L., and Knutson K.L. The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood 111 (2008) 1472-1479. In this paper, uric acid is shown to induce Th2-dependent immunoglobulins like IgG1 in the mouse, through effects on dendritic cells.
61. Sokolovska A., Hem S.L., and HogenEsch H. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine 25 (2007) 4575-4585. This paper proposes a central role for IL-1beta in causing Th2 polarization by alum in the mouse. However, no in vivo data correlate to this study.
62. Schmitz N., Kurrer M., and Kopf M. The IL-1 receptor 1 is critical for Th2 cell type airway immune responses in a mild but not in a more severe asthma model. Eur J Immunol 33 (2003) 991-1000
63. Fort M.M., Cheung J., Yen D., Li J., Zurawski S.M., Lo S., Menon S., Clifford T., Hunte B., Lesley R., et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15 (2001) 985-995
64. + T cells. J Exp Med 185 (1997) 461-469
65. Dupuis M., Murphy T.J., Higgins D., Ugozzoli M., vanNest G., Ott G., and McDonald D.M. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 186 (1998) 18-27
66. Vandepapeliere P., Horsmans Y., Moris P., van Mechelen M., Janssens M., Koutsoukos M., van Belle P., Clement F., Hanon E., Wettendorff M., et al. Vaccine adjuvants containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26 (2008) 1375-1386